

# Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Growth (Status and Outlook) 2024-2030

<https://marketpublishers.com/r/G7ABFF094608EN.html>

Date: May 2024

Pages: 109

Price: US\$ 3,660.00 (Single User License)

ID: G7ABFF094608EN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Focal segmental glomerulosclerosis (FSGS) is a type of rare kidney disease that affects the kidney's filtering system (glomeruli) resulting in proteinuria and serious scarring. Focal segmental glomerulosclerosis (FSGS) is usually fatal since it causes kidney failure within four to nine years followed by dialysis and then death. FSGS advances much more swiftly than diabetic nephropathy. Massive proteinuria, nephrotic syndrome, edema, hyperlipidemia, and hypoalbuminemia are some of the common symptoms of the disease. Risk factors include obesity, infection, sickle cell disease and reflux nephropathy.

The global Focal Segmental Glomerulosclerosis (FSGS) Treatment market size is projected to grow from US\$ 306.2 million in 2023 to US\$ 415.6 million in 2030; it is expected to grow at a CAGR of 4.5% from 2024 to 2030.

LPI (LP Information)' newest research report, the "Focal Segmental Glomerulosclerosis (FSGS) Treatment Industry Forecast" looks at past sales and reviews total world Focal Segmental Glomerulosclerosis (FSGS) Treatment sales in 2023, providing a comprehensive analysis by region and market sector of projected Focal Segmental Glomerulosclerosis (FSGS) Treatment sales for 2024 through 2030. With Focal Segmental Glomerulosclerosis (FSGS) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Focal Segmental Glomerulosclerosis (FSGS) Treatment industry.

This Insight Report provides a comprehensive analysis of the global Focal Segmental

Glomerulosclerosis (FSGS) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Focal Segmental Glomerulosclerosis (FSGS) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Focal Segmental Glomerulosclerosis (FSGS) Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Focal Segmental Glomerulosclerosis (FSGS) Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Focal Segmental Glomerulosclerosis (FSGS) Treatment.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report presents a comprehensive overview, market shares, and growth opportunities of Focal Segmental Glomerulosclerosis (FSGS) Treatment market by product type, application, key players and key regions and countries.

Segmentation by type

Drug Therapy

Dialysis

Kidney Transplant

Segmentation by application

Primary FSGS

Secondary FSGS

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

## Europe

Germany

France

UK

Italy

Russia

## Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

B. Braun Melsungen

Medtronic

Pfizer

Complexa

Dimerix

Retrophin

Beckman Coulter Inc. (Danaher)

Boston Scientific Corporation

ChemoCentryx

Variant Pharmaceuticals

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2019-2030
  - 2.1.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
- 2.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Segment by Type
  - 2.2.1 Drug Therapy
  - 2.2.2 Dialysis
  - 2.2.3 Kidney Transplant
- 2.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
  - 2.3.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
  - 2.3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type (2019-2024)
- 2.4 Focal Segmental Glomerulosclerosis (FSGS) Treatment Segment by Application
  - 2.4.1 Primary FSGS
  - 2.4.2 Secondary FSGS
- 2.5 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
  - 2.5.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
  - 2.5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application (2019-2024)

### 3 FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) TREATMENT MARKET

## **SIZE BY PLAYER**

3.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Players

3.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Players (2019-2024)

3.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Players (2019-2024)

3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

## **4 FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) TREATMENT BY REGIONS**

4.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Regions (2019-2024)

4.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)

4.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)

4.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)

4.5 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)

## **5 AMERICAS**

5.1 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2019-2024)

5.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)

5.3 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## **6 APAC**

6.1 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region (2019-2024)

6.2 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)

6.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

## **7 EUROPE**

7.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment by Country (2019-2024)

7.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)

7.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment by Region (2019-2024)

8.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)



### 8.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## 9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## 10 GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) TREATMENT MARKET FORECAST

10.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Regions (2025-2030)

10.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Regions (2025-2030)

10.1.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast

10.1.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast

10.1.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast

10.1.5 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast

10.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Country (2025-2030)

10.2.1 United States Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast

10.2.2 Canada Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast

10.2.3 Mexico Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast

10.2.4 Brazil Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast

10.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Region (2025-2030)

10.3.1 China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast

10.3.2 Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast

- 10.3.3 Korea Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
- 10.3.4 Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
- 10.3.5 India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
- 10.3.6 Australia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
- 10.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Country (2025-2030)
  - 10.4.1 Germany Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
  - 10.4.2 France Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
  - 10.4.3 UK Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
  - 10.4.4 Italy Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
  - 10.4.5 Russia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
- 10.5 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Region (2025-2030)
  - 10.5.1 Egypt Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
  - 10.5.2 South Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
  - 10.5.3 Israel Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
  - 10.5.4 Turkey Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
  - 10.5.5 GCC Countries Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
- 10.6 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Type (2025-2030)
- 10.7 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Application (2025-2030)

## **11 KEY PLAYERS ANALYSIS**

### **11.1 B. Braun Melsungen**

- 11.1.1 B. Braun Melsungen Company Information
- 11.1.2 B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
- 11.1.3 B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)

- 11.1.4 B. Braun Melsungen Main Business Overview
- 11.1.5 B. Braun Melsungen Latest Developments
- 11.2 Medtronic
  - 11.2.1 Medtronic Company Information
  - 11.2.2 Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
  - 11.2.3 Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 11.2.4 Medtronic Main Business Overview
  - 11.2.5 Medtronic Latest Developments
- 11.3 Pfizer
  - 11.3.1 Pfizer Company Information
  - 11.3.2 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
  - 11.3.3 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 11.3.4 Pfizer Main Business Overview
  - 11.3.5 Pfizer Latest Developments
- 11.4 Complexa
  - 11.4.1 Complexa Company Information
  - 11.4.2 Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
  - 11.4.3 Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 11.4.4 Complexa Main Business Overview
  - 11.4.5 Complexa Latest Developments
- 11.5 Dimerix
  - 11.5.1 Dimerix Company Information
  - 11.5.2 Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
  - 11.5.3 Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 11.5.4 Dimerix Main Business Overview
  - 11.5.5 Dimerix Latest Developments
- 11.6 Retrophin
  - 11.6.1 Retrophin Company Information
  - 11.6.2 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
  - 11.6.3 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)

- 11.6.4 Retrophin Main Business Overview
- 11.6.5 Retrophin Latest Developments
- 11.7 Beckman Coulter Inc. (Danaher)
  - 11.7.1 Beckman Coulter Inc. (Danaher) Company Information
  - 11.7.2 Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
  - 11.7.3 Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 11.7.4 Beckman Coulter Inc. (Danaher) Main Business Overview
  - 11.7.5 Beckman Coulter Inc. (Danaher) Latest Developments
- 11.8 Boston Scientific Corporation
  - 11.8.1 Boston Scientific Corporation Company Information
  - 11.8.2 Boston Scientific Corporation Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
  - 11.8.3 Boston Scientific Corporation Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 11.8.4 Boston Scientific Corporation Main Business Overview
  - 11.8.5 Boston Scientific Corporation Latest Developments
- 11.9 ChemoCentryx
  - 11.9.1 ChemoCentryx Company Information
  - 11.9.2 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
  - 11.9.3 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 11.9.4 ChemoCentryx Main Business Overview
  - 11.9.5 ChemoCentryx Latest Developments
- 11.10 Variant Pharmaceuticals
  - 11.10.1 Variant Pharmaceuticals Company Information
  - 11.10.2 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
  - 11.10.3 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 11.10.4 Variant Pharmaceuticals Main Business Overview
  - 11.10.5 Variant Pharmaceuticals Latest Developments

## **12 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Region (2019 VS 2023 VS 2030) & (\$ Millions)

Table 2. Major Players of Drug Therapy

Table 3. Major Players of Dialysis

Table 4. Major Players of Kidney Transplant

Table 5. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030) & (\$ Millions)

Table 6. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024) & (\$ Millions)

Table 7. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type (2019-2024)

Table 8. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030) & (\$ Millions)

Table 9. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024) & (\$ Millions)

Table 10. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application (2019-2024)

Table 11. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Players (2019-2024) & (\$ Millions)

Table 12. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Player (2019-2024)

Table 13. Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players Head office and Products Offered

Table 14. Focal Segmental Glomerulosclerosis (FSGS) Treatment Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)

Table 15. New Products and Potential Entrants

Table 16. Mergers & Acquisitions, Expansion

Table 17. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Regions 2019-2024 & (\$ Millions)

Table 18. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Regions (2019-2024)

Table 19. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Country/Region (2019-2024) & (\$ millions)

Table 20. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Country/Region (2019-2024)

Table 21. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2019-2024) & (\$ Millions)

Table 22. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Country (2019-2024)

Table 23. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024) & (\$ Millions)

Table 24. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type (2019-2024)

Table 25. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024) & (\$ Millions)

Table 26. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application (2019-2024)

Table 27. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region (2019-2024) & (\$ Millions)

Table 28. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Region (2019-2024)

Table 29. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024) & (\$ Millions)

Table 30. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type (2019-2024)

Table 31. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024) & (\$ Millions)

Table 32. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application (2019-2024)

Table 33. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2019-2024) & (\$ Millions)

Table 34. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Country (2019-2024)

Table 35. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024) & (\$ Millions)

Table 36. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type (2019-2024)

Table 37. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024) & (\$ Millions)

Table 38. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application (2019-2024)

Table 39. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region (2019-2024) & (\$ Millions)

Table 40. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment



Market Size Market Share by Region (2019-2024)

Table 41. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024) & (\$ Millions)

Table 42. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type (2019-2024)

Table 43. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024) & (\$ Millions)

Table 44. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application (2019-2024)

Table 45. Key Market Drivers & Growth Opportunities of Focal Segmental Glomerulosclerosis (FSGS) Treatment

Table 46. Key Market Challenges & Risks of Focal Segmental Glomerulosclerosis (FSGS) Treatment

Table 47. Key Industry Trends of Focal Segmental Glomerulosclerosis (FSGS) Treatment

Table 48. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Forecast by Regions (2025-2030) & (\$ Millions)

Table 49. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share Forecast by Regions (2025-2030)

Table 50. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Forecast by Type (2025-2030) & (\$ Millions)

Table 51. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Forecast by Application (2025-2030) & (\$ Millions)

Table 52. B. Braun Melsungen Details, Company Type, Focal Segmental Glomerulosclerosis (FSGS) Treatment Area Served and Its Competitors

Table 53. B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered

Table 54. B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 55. B. Braun Melsungen Main Business

Table 56. B. Braun Melsungen Latest Developments

Table 57. Medtronic Details, Company Type, Focal Segmental Glomerulosclerosis (FSGS) Treatment Area Served and Its Competitors

Table 58. Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered

Table 59. Medtronic Main Business

Table 60. Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 61. Medtronic Latest Developments

Table 62. Pfizer Details, Company Type, Focal Segmental Glomerulosclerosis (FSGS) Treatment Area Served and Its Competitors

Table 63. Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered

Table 64. Pfizer Main Business

Table 65. Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 66. Pfizer Latest Developments

Table 67. Complexa Details, Company Type, Focal Segmental Glomerulosclerosis (FSGS) Treatment Area Served and Its Competitors

Table 68. Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered

Table 69. Complexa Main Business

Table 70. Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 71. Complexa Latest Developments

Table 72. Dimerix Details, Company Type, Focal Segmental Glomerulosclerosis (FSGS) Treatment Area Served and Its Competitors

Table 73. Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered

Table 74. Dimerix Main Business

Table 75. Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 76. Dimerix Latest Developments

Table 77. Retrophin Details, Company Type, Focal Segmental Glomerulosclerosis (FSGS) Treatment Area Served and Its Competitors

Table 78. Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered

Table 79. Retrophin Main Business

Table 80. Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 81. Retrophin Latest Developments

Table 82. Beckman Coulter Inc. (Danaher) Details, Company Type, Focal Segmental Glomerulosclerosis (FSGS) Treatment Area Served and Its Competitors

Table 83. Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered

Table 84. Beckman Coulter Inc. (Danaher) Main Business

Table 85. Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)



- Table 86. Beckman Coulter Inc. (Danaher) Latest Developments
- Table 87. Boston Scientific Corporation Details, Company Type, Focal Segmental Glomerulosclerosis (FSGS) Treatment Area Served and Its Competitors
- Table 88. Boston Scientific Corporation Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
- Table 89. Boston Scientific Corporation Main Business
- Table 90. Boston Scientific Corporation Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)
- Table 91. Boston Scientific Corporation Latest Developments
- Table 92. ChemoCentryx Details, Company Type, Focal Segmental Glomerulosclerosis (FSGS) Treatment Area Served and Its Competitors
- Table 93. ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
- Table 94. ChemoCentryx Main Business
- Table 95. ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)
- Table 96. ChemoCentryx Latest Developments
- Table 97. Variant Pharmaceuticals Details, Company Type, Focal Segmental Glomerulosclerosis (FSGS) Treatment Area Served and Its Competitors
- Table 98. Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
- Table 99. Variant Pharmaceuticals Main Business
- Table 100. Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)
- Table 101. Variant Pharmaceuticals Latest Developments

## List Of Figures

### LIST OF FIGURES

Figure 1. Focal Segmental Glomerulosclerosis (FSGS) Treatment Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth Rate 2019-2030 (\$ Millions)

Figure 6. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Figure 7. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Country/Region (2023)

Figure 8. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Market Share by Country/Region (2019, 2023 & 2030)

Figure 9. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type in 2023

Figure 10. Focal Segmental Glomerulosclerosis (FSGS) Treatment in Primary FSGS

Figure 11. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market: Primary FSGS (2019-2024) & (\$ Millions)

Figure 12. Focal Segmental Glomerulosclerosis (FSGS) Treatment in Secondary FSGS

Figure 13. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market: Secondary FSGS (2019-2024) & (\$ Millions)

Figure 14. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application in 2023

Figure 15. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Player in 2023

Figure 16. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Regions (2019-2024)

Figure 17. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2019-2024 (\$ Millions)

Figure 18. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2019-2024 (\$ Millions)

Figure 19. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2019-2024 (\$ Millions)

Figure 20. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2019-2024 (\$ Millions)

Figure 21. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Value Market Share by Country in 2023

Figure 22. United States Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 23. Canada Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 24. Mexico Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 25. Brazil Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 26. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Region in 2023

Figure 27. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type in 2023

Figure 28. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application in 2023

Figure 29. China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 30. Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 31. Korea Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 32. Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 33. India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 34. Australia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 35. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Country in 2023

Figure 36. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type (2019-2024)

Figure 37. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application (2019-2024)

Figure 38. Germany Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 39. France Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 40. UK Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size

Growth 2019-2024 (\$ Millions)

Figure 41. Italy Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size

Growth 2019-2024 (\$ Millions)

Figure 42. Russia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size

Growth 2019-2024 (\$ Millions)

Figure 43. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Region (2019-2024)

Figure 44. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type (2019-2024)

Figure 45. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application (2019-2024)

Figure 46. Egypt Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size

Growth 2019-2024 (\$ Millions)

Figure 47. South Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 48. Israel Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 49. Turkey Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 50. GCC Country Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 51. Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 52. APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 53. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 54. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 55. United States Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 56. Canada Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 57. Mexico Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 58. Brazil Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 59. China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 60. Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 61. Korea Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 62. Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 63. India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 64. Australia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 65. Germany Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 66. France Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 67. UK Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 68. Italy Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 69. Russia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 70. Spain Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 71. Egypt Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 72. South Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 73. Israel Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 74. Turkey Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 75. GCC Countries Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2025-2030 (\$ Millions)

Figure 76. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share Forecast by Type (2025-2030)

Figure 77. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share Forecast by Application (2025-2030)

## I would like to order

Product name: Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Growth (Status and Outlook) 2024-2030

Product link: <https://marketpublishers.com/r/G7ABFF094608EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7ABFF094608EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

